MGAT5 alters the severity of multiple sclerosis

B. Brynedal, J. Wojcik, F. Esposito, V. Debailleul, J. Yaouanq, F. Martinelli-Boneschi, G. Edan, G. Comi, J. Hillert, H. Abderrahim

Research output: Contribution to journalArticlepeer-review


Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Mar 30 2010


  • Genetic association
  • MGAT5
  • MSSS
  • Multiple sclerosis
  • Severity

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology


Dive into the research topics of 'MGAT5 alters the severity of multiple sclerosis'. Together they form a unique fingerprint.

Cite this